Asset Details
Do you wish to reserve the book?
Extracellular RNA as a molecular driver and therapeutic target in abdominal aortic aneurysms
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Extracellular RNA as a molecular driver and therapeutic target in abdominal aortic aneurysms
Do you wish to request the book?
Extracellular RNA as a molecular driver and therapeutic target in abdominal aortic aneurysms
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Extracellular RNA as a molecular driver and therapeutic target in abdominal aortic aneurysms
2025
Overview
Abdominal aortic aneurysms (AAAs) are characterized by chronic inflammation, matrix degradation and smooth muscle cell (SMC) loss, leading to vessel dilation and rupture, with no current pharmaceutical management options. Since recent studies have highlighted the role of extracellular (ex) nucleic acids in promoting inflammation and tissue damage in cardiovascular conditions, we aimed to characterize the contribution of exDNA and exRNA to AAA pathogenesis and evaluate their potential as therapeutic targets in established disease. Circulating exDNA was elevated in patients and mouse models, while plasma levels of exRNA were not associated with AAA development. When RNase A or DNase I was administered to mice with established disease, the targeted degradation of exRNA, but not exDNA, significantly attenuated aneurysm growth. The RNase A treatment produced systemic anti-inflammatory effects (reduced monocyte/granulocyte count) and showed the potential to improve local vascular conditions by preserving SMC integrity, reducing macrophage infiltration and protease expression. These effects were not observed in DNase I-treated animals. In conclusion, while circulating exDNA showed AAA biomarker potential, targeting exRNA by systemic RNase A treatment effectively mitigated aneurysm progression in established disease through pleiotropic modulation of inflammation and tissue remodeling, presenting a novel and promising therapeutic strategy.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/4017
/ 692/420
/ 692/699
/ Abdomen
/ Aged
/ Animals
/ Aortic Aneurysm, Abdominal - blood
/ Aortic Aneurysm, Abdominal - drug therapy
/ Aortic Aneurysm, Abdominal - genetics
/ Aortic Aneurysm, Abdominal - metabolism
/ Aortic Aneurysm, Abdominal - pathology
/ Cell-Free Nucleic Acids - blood
/ Cloning
/ Deoxyribonuclease I - pharmacology
/ Ethics
/ Female
/ Humanities and Social Sciences
/ Humans
/ Ketamine
/ Male
/ Mice
/ Myocytes, Smooth Muscle - metabolism
/ Plasma
/ Ribonuclease, Pancreatic - pharmacology
/ Science
